Vaughan David Investments’s Thermo Fisher Scientific TMO Stock Holding History

Vaughan David Investments’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-509	Closed	-$293K	–	204
2023 Q1	$293K	Hold	509	–	–	0.01%	172
2022 Q4	$280K	Buy	+509	New	+$270K	0.01%	173

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Vaughan David Investments's TMO Position: Q2 2023 in Review

Vaughan David Investments sold out of Thermo Fisher Scientific (TMO) in Q2 2023, closing a stake of 509 shares — an estimated $293K sold.

Vaughan David Investments first reported a position in TMO in Q4 2022 and held it in 2 quarters. The position peaked at $293K in Q1 2023. 2,387 funds tracked by Wall St. Rank hold TMO as of Q2 2023.

Vaughan David Investments reported no remaining Thermo Fisher Scientific position as of Q2 2023 after selling out during the quarter.
Vaughan David Investments sold 509 Thermo Fisher Scientific shares in Q2 2023, an estimated $293K.
Vaughan David Investments first reported a position in Thermo Fisher Scientific in Q4 2022 and held it in 2 quarters.
Vaughan David Investments's Thermo Fisher Scientific position peaked at $293K in Q1 2023.
2,387 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2023.

Based on Vaughan David Investments's 13F filing for Q2 2023, filed 2 Aug 2023.